MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31, ANIP made $237,462K in revenue. $29,492K in net income. Net profit margin of 12.42%.

Income Overview

Revenue
$237,462K
Net Income
$29,492K
Net Profit Margin
12.42%
EPS
$1.28
Unit: Thousand (K) dollars
Revenue Breakdown
    • Sales Of Generic Pharmaceutical ...
    • Sales Of Cortrophin Gel
    • Sales Of Established Brand Royal...
    • Others

Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Net revenues
237,462 224,592* 227,813 211,371
Cost of sales (excluding depreciation and amortization)
93,582 90,897* 93,389 74,615
Research and development
10,600 8,406* 12,304 16,535
Gain on sale of building
---0
Selling, general, and administrative
73,655 80,105* 76,656 81,771
Depreciation and amortization
20,919 22,548* 22,632 23,281
Contingent consideration fair value adjustment
-182 -11,222* -14,470 1,277
Gain (loss) on disposal of assets
-503* -295 -
Restructuring activities
-0* --
Intangible asset impairment charge
--1,534* 767 -
Total operating expenses, net
198,574 188,695* 191,573 197,479
Operating income
38,888 35,897* 36,240 13,892
Unrealized loss (gain) on investment in equity securities
5,753 -2,384* 3,140 332
Interest expense, net
-3,769 -4,812* -4,727 -5,438
Other (expense) income, net
-651 605* -853 1,739
Loss on extinguishment of debt
-0* 0 -
Income before income tax expense
40,221 29,305* 33,800 10,525
Income tax expense
10,729 3,716* 7,183 1,976
Net income
29,492 25,589* 26,617 8,549
Dividends on series a convertible preferred stock
0 31* 344 407
Net income available to common shareholders
29,492 25,558 26,273 8,142
Basic EPS
1.31 1.262 1.19 0.37
Diluted EPS
1.28 1.147 1.13 0.36
Basic Average Shares
20,914,000 20,251,000 20,074,000 19,834,000
Diluted Average Shares
21,544,000 22,283,000 21,093,000 20,308,000
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Sales Of CortrophinGel$75,119K Sales Of ILUVIENAndYUTIQ$19,255K Total Sales Of RareDisease Pharmaceutical...$94,374K Sales Of EstablishedBrand Royalties And...$21,540K Sales Of EstablishedBrands$12,328K Sales Of GenericPharmaceutical Products$105,402K Sales Of Generic OtherRevenues$3,818K Total Sales Of RareDisease And Brands$128,242K Total Sales OfGenerics And Other$109,220K Net revenues$237,462K Operating income$38,888K Unrealized loss (gain) oninvestment in equity...$5,753K Total operatingexpenses, net$198,574K Contingent considerationfair value...-$182K Income before incometax expense$40,221K Interest expense, net-$3,769K Other (expense)income, net-$651K Cost of sales(excluding depreciation...$93,582K Selling, general, andadministrative$73,655K Depreciation andamortization$20,919K Research and development$10,600K Net income$29,492K Income tax expense$10,729K Net incomeavailable to common...$29,492K

ANI PHARMACEUTICALS INC (ANIP)

ANI PHARMACEUTICALS INC (ANIP)